ProCE Banner Activity

Immune Checkpoint Inhibitor Therapy for HER2-Negative Early-Stage Breast Cancer

Slideset

Expert slides from Tanya Gupta, MD, on key data supporting immune checkpoint inhibitor–based therapy for treatment of early-stage triple-negative breast cancer.

Released: May 16, 2024

Expiration: May 15, 2025

Share

Faculty

Tanya Gupta

Tanya Gupta, MD

Clinical Assistant Professor
Breast Oncology
Stanford Healthcare
Palo Alto, California

Provided by

Provided by Clinical Care Options, LLC in partnership with Breastcancer.org

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Merck Sharp & Dohme, LLC, and Novartis Pharmaceuticals Corporation.

AstraZeneca

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Partners

Breastcancer.org

ProCE Banner